Journal of Literature Pharmacy Sciences

Oküler İlaç Taşıyıcı Sistemler: Geleneksel Derleme
Ocular Drug Delivery Systems: Traditional Review
Heybet Kerem POLATa, Sedat ÜNALb, Eren AYTEKİNc, Sefa GÖZCÜd
aSağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu, Ankara, Türkiye
bErciyes Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji ABD, Kayseri, Türkiye
cHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji ABD, Ankara, Türkiye
dErzincan Binali Yıldırım Üniversitesi Eczacılık Fakültesi, Farmakognozi ABD, Erzincan, Türkiye
J Lit Pharm Sci. 2022;11(3):189-200
doi: 10.5336/pharmsci.2022-93906
Article Language: TR
Full Text
ÖZET
 Oküler ilaç uygulamaları, gözün yapısal karmaşıklığı ve savunma mekanizmaları nedeniyle oftalmologlar ve oküler ilaç taşıyıcı sistemler üzerine çalışan bilim insanları için çok zorlu bir alandır. Farklı kornea katmanları, sklera, konjonktival kan akışı, gözyaşı seyreltmesi ve kan retina bariyeri gibi engeller, gözün anterior ve posterior kısımlarına ilaç uygulanması etkinliğini sınırlamaktadır. Konvansiyonel oküler ilaç uygulama şekilleri arasında oküler göz damlası tüketiciler tarafından yaygın olarak tercih edilmektedir. Fakat bu göz damlalarının oküler bariyerlerden emilimi sınırlı olduğu için düşük biyoyararlanıma sahiptir bu sebeple sık uygulama gerektirmektedir. Bu durum ise hasta uyuncunu azaltmaktadır. Ayrıca bazı durumlarda etkin maddenin çözelti şeklinde hazırlanması mümkün olmamaktadır. Bu sebeple yine damla şeklinde kullanılabilen süspansiyon, emülsiyon gibi farklı dozaj şekilleri de geliştirilmeye çalışılmaktadır. Fakat bu tarz formülasyonlar da formülasyona bağlı stabilite ve yüksek viskozite gibi ciddi sıkıntılar barındırmaktadır. Hem gözün yapısal sorunları hem de dozaj şekillerinde istenilen etkilerin elde edilememesi araştırmacıları farklı çalışmalara itmektedir. Bu nedenle bilim insanları, göze ilaç verme potansiyelini ve dolayısıyla tedavi etkinliğini artırmak için çeşitli ilaç taşıyıcı sistemleri tasarlamış ve incelemişlerdir. Nanopartikül, lipozom, mikroemülsiyon, insert ve ilaç yüklü kontakt lens gibi yeni ilaç taşıyıcı sistemler son zamanlarda geleneksel ilaç taşıyıcı sistemlere alternatif olarak araştırılmaktadır. Bu tarz yeni ilaç taşıyıcı sistemler oküler ilaç uygulama açısından umut verici olsa da üstesinden gelinmesi gereken sorunlar da bulunmaktadır. Bu derlemede çeşitli geleneksel ve yeni ilaç taşıyıcı formülasyonlar özetlenmeye çalışılmıştır.

Anahtar Kelimeler: Göz; göz damlası; oküler ilaç taşıyıcı sistemler
ABSTRACT
 Ocular drug applications are a challenging area for ophthalmologists and scientists developing drug delivery systems due to the structural and barrier complexity of the eye. Obstacles such as different corneal layers, sclera, conjunctival blood flow, tear dilution, and blood retinal barrier limit the effectiveness of drug administration to the anterior and posterior parts of the eye. Among the conventional ocular drug administration forms, ocular eye drops are widely preferred by patients. However, these eye drops have low bioavailability due to the ocular barrier and therefore require frequent application. This situation reduces patient compliance. In addition, in some cases, it isn't possible to prepare the active substance in solution form. For this reason, different dosage forms such as suspension and emulsion, which can be used in drops form, are also being developed. However, such formulations also have serious problems such as formulation-related stability and high viscosity. Both the structural problems of the eye and the inability to achieve the desired effects in dosage forms push researchers to different studies. For this reason, scientists have designed and studied various drug delivery systems to increase the drug delivery potential to the eye and thus the treatment efficacy. New drug delivery systems such as nanoparticles, liposomes, microemulsions, inserts, and drug-loaded contact lenses have recently been investigated as an alternative to conventional drug delivery systems. Although such new drug delivery systems provide a glimmer of hope for ocular drug delivery, there are still problems to be overcome. In this review, various traditional and new drug delivery formulations have been tried to be summarized.

Keywords: Eye; eye drop; ocular drug delivery systems
REFERENCES:
  1. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131-5. [Crossref]  [PubMed] 
  2. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems--recent advances. Prog Retin Eye Res. 1998;17(1):33-58. [Crossref]  [PubMed] 
  3. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47-64. [Crossref]  [PubMed]  [PMC] 
  4. Qamar Z, Qizilbash FF, Iqubal MK, Ali A, Narang JK, Ali J, et al. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective. Recent Pat Drug Deliv Formul. 2019;13(4):246-54. [Crossref]  [PubMed]  [PMC] 
  5. Aksu B, Mesut B. Quality by design (QbD) for pharmaceutical area. J Pharm Istanbul Univ. 2015;45(2):233-51. [Link] 
  6. Bozdag S, Weyenberg W, Adriaens E, Dhondt MM, Vergote V, Vervaet C, et al. In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops. Drug Dev Ind Pharm. 2010;36(11):1259-70. [Crossref]  [PubMed] 
  7. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3(2):275-87. [Crossref]  [PubMed] 
  8. Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370(3):602-24. [Crossref]  [PubMed] 
  9. Patel P, Shastri D, Shelat P, Shukla A. Ophthalmic drug delivery system: challenges and approaches. Sys Rev Pharm. 2010;1(2):113-20. [Crossref] 
  10. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15-34. [Crossref]  [PubMed] 
  11. Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, Mao Z, Riancho L, Faure MO, et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis. 2008;14:204-16. [PubMed]  [PMC] 
  12. Yamaguchi M, Ueda K, Isowaki A, Ohtori A, Takeuchi H, Ohguro N, et al. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull. 2009;32(7):1266-71. [Crossref]  [PubMed] 
  13. Polat HK, Kurt N, Aytekin E, Bozdağ Pehlivan S, Çalış S. Novel drug delivery systems to improve the treatment of keratitis. J Ocul Pharmacol Ther. 2022;38(6):376-95. [Crossref]  [PubMed] 
  14. Rozi MF, Sabere ASM. A Review on conventional and novel topical ocular drug delivery system. J Pharm Pharmacol. 2021;1(1):19-26. [Crossref] 
  15. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473-93. [Crossref]  [PubMed] 
  16. Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11(3):866-93. [Crossref]  [PubMed] 
  17. Scoper SV, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, et al. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension. Adv Ther. 2008;25(2):77-88. [Crossref]  [PubMed] 
  18. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst. 1999;16(1):85-146. [Crossref]  [PubMed] 
  19. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterisation and research methods. ScientificWorldJournal. 2014;2014:861904. [Crossref]  [PubMed]  [PMC] 
  20. Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev. 2006;58(11):1258-68. [Crossref]  [PubMed] 
  21. Sheshala R, Kok YY, Ng JM, Thakur RR, Dua K. In situ gelling ophthalmic drug delivery system: an overview and its applications. Recent Pat Drug Deliv Formul. 2015;9(3):237-48. [Crossref]  [PubMed] 
  22. Ishibashi T, Yokoi N, Bron AJ, Tiffany JM, Komuro A, Kinoshita S. Retention of reversibly thermo-gelling timolol on the human ocular surface studied by video meniscometry. Curr Eye Res. 2003;27(2):117-22. [Crossref]  [PubMed] 
  23. Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, et al; Brimonidine 0.15% Study Group. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology. 2006;113(8):1333-9. [Crossref]  [PubMed] 
  24. Ranch K, Patel H, Chavda L, Koli A, Maulvi F, Parikh RK. Development of in situ ophthalmic gel of dexamethasone sodium phosphate and chloramphenicol: a viable alternative to conventional eye drops. J Appl Pharm Sci. 2017;7(3):101-8. [Crossref] 
  25. Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000;199(2):119-27. [Crossref]  [PubMed] 
  26. Polat HK. In situ gels triggered by temperature for ocular delivery of dexamethasone and dexamethasone/SBE-β-CD complex. J Res Pharm. 2022;26(4):873-83. [Crossref] 
  27. Fang G, Yang X, Wang Q, Zhang A, Tang B. Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases. Mater Sci Eng C Mater Biol Appl. 2021;127:112212. [Crossref]  [PubMed] 
  28. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3-4):144-51. [Crossref]  [PubMed] 
  29. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des. 2009;15(23):2724-50. [Crossref]  [PubMed] 
  30. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197-216. [Crossref]  [PubMed]  [PMC] 
  31. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 2001;33(1):31-6. [Crossref]  [PubMed] 
  32. de Campos AM, Diebold Y, Carvalho EL, Sánchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21(5):803-10. Erratum in: Pharm Res. 2005;22(6):1007. [Crossref]  [PubMed] 
  33. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm. 2008;68(3):513-25. [Crossref]  [PubMed] 
  34. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010;17(7):467-89. [Crossref]  [PubMed] 
  35. Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 2013;39(4):508-19. [Crossref]  [PubMed] 
  36. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238(1-2):241-5. [Crossref]  [PubMed] 
  37. Polat HK, Kurt N, Aytekin E, Akdağ Çaylı Y, Bozdağ Pehlivan S, Çalış S. Design of besifloxacin hcl-loaded nanostructured lipid carriers: in vitro and ex vivo evaluation. J Ocul Pharmacol Ther. 2022;38(6):412-23. [Crossref]  [PubMed] 
  38. Aytekin E, Öztürk N, Vural İ, Polat HK, Çakmak HB, Çalış S, et al. Design of ocular drug delivery platforms and in vitro - in vivo evaluation of riboflavin to the cornea by non-interventional (epi-on) technique for keratoconus treatment. J Control Release. 2020;324:238-49. [Crossref]  [PubMed] 
  39. Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm J. 2021;29(9):999-1012. [Crossref]  [PubMed]  [PMC] 
  40. Andrade LM, Rocha KA, De Sá FA, Marreto RN, Lima EM, Gratieri T, et al. Voriconazole-loaded nanostructured lipid carriers for ocular drug delivery. Cornea. 2016;35(6):866-71. [Crossref]  [PubMed] 
  41. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89-121. [Crossref]  [PubMed] 
  42. Bharti SK, Kesavan K. Phase-transition W/O microemulsions for ocular delivery: evaluation of antibacterial activity in the treatment of bacterial keratitis. Ocul Immunol Inflamm. 2017;25(4):463-74. [Crossref]  [PubMed] 
  43. Üstündağ Okur N, Çağlar EŞ, Siafaka PI. Novel ocular drug delivery systems: an update on microemulsions. J Ocul Pharmacol Ther. 2020;36(6):342-54. [Crossref]  [PubMed] 
  44. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1-2):126-33. [Crossref]  [PubMed] 
  45. Ali HS, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2011;149(2):175-81. [Crossref]  [PubMed] 
  46. Zhang L, Zhang Q, Wang X, Zhang W, Lin C, Chen F, et al. Drug-in-cyclodextrin-in-liposomes: a novel drug delivery system for flurbiprofen. Int J Pharm. 2015;492(1-2):40-5. [Crossref]  [PubMed] 
  47. Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18(5-6):290-7. [Crossref]  [PubMed] 
  48. Chetoni P, Burgalassi S, Monti D, Najarro M, Boldrini E. Liposome-encapsulated mitomycin C for the reduction of corneal healing rate and ocular toxicity. J Drug Deliv Sci Technol. 2007;17(1):43-8. [Crossref] 
  49. Budai L, Hajdú M, Budai M, Gróf P, Béni S, Noszál B, et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm. 2007;343(1-2):34-40. [Crossref]  [PubMed] 
  50. Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J. 2007;9(3):E371-7. [Crossref]  [PubMed]  [PMC] 
  51. Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol. 2010;88(8):901-4. [Crossref]  [PubMed] 
  52. Zhang J, Wang S. Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm. 2009;372(1-2):66-75. [Crossref]  [PubMed] 
  53. Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm. 2010;36(1):108-18. [Crossref]  [PubMed] 
  54. Yavuz B, Pehlivan SB, Unlü N. Dendrimeric systems and their applications in ocular drug delivery. ScientificWorldJournal. 2013;2013:732340. [Crossref]  [PubMed]  [PMC] 
  55. Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv. 2012;9(4):421-30. [Crossref]  [PubMed] 
  56. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102(1):23-38. [Crossref]  [PubMed] 
  57. Kalomiraki M, Thermos K, Chaniotakis NA. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 2015;11:1-12. [Crossref]  [PubMed]  [PMC] 
  58. Gupta H, Aqil M. Contact lenses in ocular therapeutics. Drug Discov Today. 2012;17(9-10):522-7. [Crossref]  [PubMed] 
  59. Kim J, Chauhan A. Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. Int J Pharm. 2008;353(1-2):205-22. [PubMed] 
  60. Gulsen D, Li CC, Chauhan A. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Curr Eye Res. 2005;30(12):1071-80. [Crossref]  [PubMed] 
  61. White CJ, Byrne ME. Molecularly imprinted therapeutic contact lenses. Expert Opin Drug Deliv. 2010;7(6):765-80. [Crossref]  [PubMed] 
  62. Tieppo A, White CJ, Paine AC, Voyles ML, McBride MK, Byrne ME. Sustained in vivo release from imprinted therapeutic contact lenses. J Control Release. 2012;157(3):391-7. [Crossref]  [PubMed] 
  63. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187-207. [Crossref]  [PubMed]  [PMC] 
  64. Bhatnagar S, Saju A, Cheerla KD, Gade SK, Garg P, Venuganti VVK. Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles. Drug Deliv Transl Res. 2018;8(3):473-83. [Crossref]  [PubMed] 
  65. Jiang J, Gill HS, Ghate D, McCarey BE, Patel SR, Edelhauser HF, et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci. 2007;48(9):4038-43. [Crossref]  [PubMed] 
  66. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26(2):395-403. [Crossref]  [PubMed]  [PMC] 
  67. Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. 2011;28(1):166-76. [Crossref]  [PubMed]  [PMC] 
  68. Grass GM, Cobby J, Makoid MC. Ocular delivery of pilocarpine from erodible matrices. J Pharm Sci. 1984;73(5):618-21. [Crossref]  [PubMed] 
  69. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev. 1995;16(1):95-106. [Crossref] 
  70. Üstündağ-Okur N, Gökçe EH, Bozbıyık Dİ, Eğrilmez S, Ertan G, Özer Ö. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Expert Opin Drug Deliv. 2015;12(11):1791-807. [Crossref]  [PubMed] 
  71. Polat HK, Bozdağ Pehlivan S, Özkul C, Çalamak S, Öztürk N, Aytekin E, et al. Development of besifloxacin HCl loaded nanofibrous ocular inserts for the treatment of bacterial keratitis: In vitro, ex vivo and in vivo evaluation. Int J Pharm. 2020;585:119552. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com